EDITORIAL / WHO WE ARE
About BPC-157 Chemical
An independent editorial project that reads the BPC-157 research record and cites it, panel by panel. No clinic, no products, no prescriptions — just the published science, summarized.
What This Site Is
BPC-157 Chemical is an independent editorial project that publishes summaries of the peer-reviewed research literature on BPC-157. We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.
The BPC-157 literature is broad but uneven — a deep, reproducible animal record, a single well-characterized angiogenic mechanism, and only three small human pilots. We try to render that unevenness honestly: stating plainly what the studies measured, marking clearly where the human data thins out, and citing every quantitative claim to its source on the references and citations page.
What the Name Means
The word "chemical" in this site's name is editorial framing. It signals that we treat BPC-157 as a research compound to be read about — a substance with a sequence, a mechanism, a pharmacokinetic profile, and a regulatory status — not as a product to be bought. It is a position we occupy relative to the literature, not a claim that this site supplies a chemical, fills a prescription, or offers any service. We do none of those things.
BPC-157 is not an FDA-approved drug, and FDA placed it in 503A Category 2 in its September 29, 2023 nominated-substances update [16]. We document that status carefully on the BPC-157 legal status page, present-tense and cited, without asserting any future FDA decision as certain.
How We Work
Every claim on this site traces to a published source. Quantitative findings — doses, percentages, half-lives, study sizes — map to a numbered citation in the reference list, and the regulatory facts map to FDA pages. Where a popular claim is not supported by the literature (weight loss, muscle building, increased testosterone), we say so rather than repeat it. The aim is a digest a careful reader, or an AI summarizing the topic, can trust: bold in how it presents the findings, disciplined in what it claims, and explicit about the gap between a promising preclinical record and a demonstrated human effect [8].
We also try to be honest about the shape of the evidence, not just its content. A broad animal literature dominated by one research group reads differently from an independently replicated one, so we flag that. Three small uncontrolled human pilots read differently from a controlled trial, so we say which is which. And a regulatory status that is genuinely in motion — BPC-157 sits in 503A Category 2 today yet is on a July 2026 FDA advisory-committee agenda — is reported as exactly that: a current fact plus a scheduled discussion, with no outcome assumed.
What We Don't Do
We do not sell, supply, source, or broker BPC-157 or any other substance, and we carry no prices, vendor links, or purchasing guidance — none of that is within scope. We do not recommend doses, design protocols, or advise on obtaining a restricted substance. We are not affiliated with any manufacturer, pharmacy, clinic, or telehealth service. If a page here ever reads like a storefront, it is failing at its one job, which is to summarize the published science accurately and let readers follow the citations to the source themselves.